Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States.

Farrell DJ, Mendes RE, Bensaci M.

Diagn Microbiol Infect Dis. 2019 Jan;93(1):85-88. doi: 10.1016/j.diagmicrobio.2018.08.006. Epub 2018 Aug 23.

PMID:
30314652
2.

Comparative activity of silver-based antimicrobial composites for urinary catheters.

Thokala N, Kealey DC, Kennedy DJ, Brady DDB, Farrell DJ.

Int J Antimicrob Agents. 2018 Aug;52(2):166-171. doi: 10.1016/j.ijantimicag.2018.03.015. Epub 2018 Apr 5.

PMID:
29626618
3.

Primary Posterior Blade Plate Tibiotalar Arthrodesis: A Salvage Procedure for Complex Nonreconstructable Pilon Fractures.

Abebe E, Farrell DJ, Zelle B, Gruen G.

J Orthop Trauma. 2017 Aug;31 Suppl 3:S30-S33. doi: 10.1097/BOT.0000000000000911. Review.

PMID:
28697082
4.

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00468-17. doi: 10.1128/AAC.00468-17. Print 2017 Jul.

5.

Short-Read Whole-Genome Sequencing for Laboratory-Based Surveillance of Bordetella pertussis.

Marchand-Austin A, Tsang RSW, Guthrie JL, Ma JH, Lim GH, Crowcroft NS, Deeks SL, Farrell DJ, Jamieson FB.

J Clin Microbiol. 2017 May;55(5):1446-1453. doi: 10.1128/JCM.02436-16. Epub 2017 Feb 22.

6.

In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16. doi: 10.1128/AAC.02047-16. Print 2017 Mar.

7.

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.

Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN.

J Glob Antimicrob Resist. 2017 Mar;8:28-32. doi: 10.1016/j.jgar.2016.08.013. Epub 2016 Nov 2.

PMID:
27939809
8.

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.

Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN.

J Antimicrob Chemother. 2016 Dec;71(12):3453-3458. Epub 2016 Sep 8.

PMID:
27609052
9.

In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Flamm RK, Rhomberg PR, Huband MD, Farrell DJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.

10.
11.

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents.

Flamm RK, Rhomberg PR, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2016 Sep;86(1):66-9. doi: 10.1016/j.diagmicrobio.2016.06.012. Epub 2016 Jun 16.

PMID:
27352729
12.

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).

Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN.

Int J Antimicrob Agents. 2016 Aug;48(2):144-50. doi: 10.1016/j.ijantimicag.2016.04.021. Epub 2016 May 24.

PMID:
27291285
13.

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).

Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2016 Jun;47(6):495-9. doi: 10.1016/j.ijantimicag.2016.04.009. Epub 2016 May 12.

PMID:
27211209
14.

In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11. doi: 10.1128/AAC.00627-16. Print 2016 Jul.

15.

Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure.

Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS.

Pediatr Infect Dis J. 2016 Jul;35(7):813-5. doi: 10.1097/INF.0000000000001171.

PMID:
27093165
16.

Results from the Solithromycin International Surveillance Program (2014).

Farrell DJ, Flamm RK, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2016 May 23;60(6):3662-8. doi: 10.1128/AAC.00185-16. Print 2016 Jun.

17.

Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.

Farrell DJ, Mendes RE, Castanheira M, Jones RN.

Antimicrob Agents Chemother. 2016 May 23;60(6):3827-31. doi: 10.1128/AAC.00238-16. Print 2016 Jun.

18.

Comparison of BD Max StaphSR and BD Max MRSAXT for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States.

Mendes RE, Watters AA, Rhomberg PR, Farrell DJ, Jones RN.

J Clin Microbiol. 2016 Jun;54(6):1668-1669. doi: 10.1128/JCM.00374-16. Epub 2016 Mar 23. No abstract available.

19.

Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.

Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2016 May 23;60(6):3817-20. doi: 10.1128/AAC.00281-16. Print 2016 Jun.

20.

Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.

Sader HS, Farrell DJ, Flamm RK, Jones RN.

Surg Infect (Larchmt). 2016 Aug;17(4):443-7. doi: 10.1089/sur.2015.209. Epub 2016 Mar 18.

PMID:
26990170
21.

Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals.

Sader HS, Farrell DJ, Flamm RK, Streit JM, Mendes RE, Jones RN.

Diagn Microbiol Infect Dis. 2016 May;85(1):80-4. doi: 10.1016/j.diagmicrobio.2016.01.010. Epub 2016 Jan 22.

PMID:
26971182
22.

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.

Flamm RK, Nichols WW, Sader HS, Farrell DJ, Jones RN.

Int J Antimicrob Agents. 2016 Mar;47(3):235-42. doi: 10.1016/j.ijantimicag.2016.01.004. Epub 2016 Feb 3.

PMID:
26920105
23.

Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.

Sader HS, Flamm RK, Mendes RE, Farrell DJ, Jones RN.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2558-63. doi: 10.1128/AAC.02794-15. Print 2016 Apr.

24.

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.

Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader HS.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.

25.

Ceftaroline activity tested against viridans group streptococci from US hospitals.

Sader HS, Rhomberg PR, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN.

Diagn Microbiol Infect Dis. 2016 Mar;84(3):232-5. doi: 10.1016/j.diagmicrobio.2015.10.028. Epub 2015 Nov 3.

PMID:
26658313
26.

Plate augmentation for femoral nonunion: more than just a salvage tool?

Chiang JC, Johnson JE, Tarkin IS, Siska PA, Farrell DJ, Mormino MA.

Arch Orthop Trauma Surg. 2016 Feb;136(2):149-56. doi: 10.1007/s00402-015-2365-9. Epub 2015 Dec 8.

PMID:
26646845
27.

In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.

Armstrong ES, Farrell DJ, Palchak M, Steenbergen JN.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):666-8. doi: 10.1128/AAC.01964-15. Print 2016 Jan.

28.

A hot-electron thermophotonic solar cell demonstrated by thermal up-conversion of sub-bandgap photons.

Farrell DJ, Sodabanlu H, Wang Y, Sugiyama M, Okada Y.

Nat Commun. 2015 Nov 6;6:8685. doi: 10.1038/ncomms9685.

30.

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).

Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN.

J Antimicrob Chemother. 2016 Jan;71(1):276-8. doi: 10.1093/jac/dkv303. Epub 2015 Oct 7. No abstract available.

PMID:
26451012
31.

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.

Sader HS, Rhomberg PR, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):379-81. doi: 10.1016/j.diagmicrobio.2015.08.013. Epub 2015 Aug 28.

PMID:
26415906
32.

Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.

Riedel S, Ross JE, Farrell DJ, Flamm RK, Jones RN.

J Clin Microbiol. 2015 Dec;53(12):3888-90. doi: 10.1128/JCM.02250-15. Epub 2015 Sep 16.

33.

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).

Sader HS, Farrell DJ, Flamm RK, Jones RN.

J Glob Antimicrob Resist. 2015 Sep;3(3):161-165. doi: 10.1016/j.jgar.2015.04.003. Epub 2015 May 22.

PMID:
27873705
34.

Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program.

Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ, Mendes RE.

Antimicrob Agents Chemother. 2015 Oct;59(10):6256-61. doi: 10.1128/AAC.01473-15. Epub 2015 Jul 27.

35.

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.

Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN, Flamm RK.

Microb Drug Resist. 2016 Jan;22(1):53-8. doi: 10.1089/mdr.2014.0307. Epub 2015 Jul 31.

36.

Wedge effect following intramedullary hip screw fixation of intertrochanteric proximal femur fracture.

O'Malley MJ, Kang KK, Azer E, Siska PA, Farrell DJ, Tarkin IS.

Arch Orthop Trauma Surg. 2015 Oct;135(10):1343-7. doi: 10.1007/s00402-015-2280-0. Epub 2015 Jul 19.

PMID:
26188523
37.

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).

Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2015 Oct;83(2):183-6. doi: 10.1016/j.diagmicrobio.2015.06.011. Epub 2015 Jun 23.

PMID:
26164275
38.

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).

Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):389-94. doi: 10.1016/j.diagmicrobio.2015.06.008. Epub 2015 Jun 17.

PMID:
26162518
39.

Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012.

Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D Jr, Farrell DJ.

Antimicrob Agents Chemother. 2015 Sep;59(9):5595-601. doi: 10.1128/AAC.00182-15. Epub 2015 Jun 29.

40.
41.

Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.

Mendes RE, Farrell DJ, Flamm RK, Sader HS, Jones RN.

J Clin Microbiol. 2015 Aug;53(8):2727-30. doi: 10.1128/JCM.00611-15. Epub 2015 May 27.

42.

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.

Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN.

Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.

PMID:
25956844
43.

Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.

Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN.

Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.

44.

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).

Sader HS, Farrell DJ, Flamm RK, Jones RN.

J Antimicrob Chemother. 2015 Jul;70(7):2053-6. doi: 10.1093/jac/dkv076. Epub 2015 Mar 25.

PMID:
25814163
45.

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Sader HS, Rhomberg PR, Farrell DJ, Jones RN.

Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.

46.

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.

Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE.

Diagn Microbiol Infect Dis. 2015 May;82(1):73-7. doi: 10.1016/j.diagmicrobio.2015.01.017. Epub 2015 Feb 7.

PMID:
25724854
47.

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).

Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN.

J Glob Antimicrob Resist. 2015 Mar;3(1):36-39. doi: 10.1016/j.jgar.2014.12.003. Epub 2015 Jan 17.

48.

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M, Jones RN.

Diagn Microbiol Infect Dis. 2015 May;82(1):78-84. doi: 10.1016/j.diagmicrobio.2015.01.015. Epub 2015 Feb 10.

PMID:
25708896
49.

Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ.

Antimicrob Agents Chemother. 2015 May;59(5):2583-7. doi: 10.1128/AAC.05119-14. Epub 2015 Feb 17.

50.

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN.

Antimicrob Agents Chemother. 2015 Apr;59(4):2458-61. doi: 10.1128/AAC.04614-14. Epub 2015 Feb 2.

Supplemental Content

Loading ...
Support Center